MedTrace Logo

A Prospective Observational Study on Efficacy of TARE for Early Stage HCC

NCT07278102 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-12-11

No results posted yet for this study

Summary

The aim of the current study is to analyze treatment outcomes (best target lesion response, overall survival, time to target lesion progression, time to overall progression, and treatment-related adverse event) using prospectively collected clinical and imaging data in patients with BCLC 0 or A HCCs treated with TheraSphere® in four large-volume hospitals from Korea. The results will pave the way for expanding 90Y-TARE indication and refining reimbursement guidelines, and provide baseline data for possible subsequent future studies.

Conditions

  • Radioembolization
  • Hepatocellular Carcinoma (HCC)
  • Early Stage

Interventions

PROCEDURE

transarterial radioembolization

TARE with 90Y

Sponsors & Collaborators

  • National Cancer Center, Korea

    collaborator OTHER_GOV

  • Severance Hospital

    collaborator OTHER

  • Samsung Medical Center

    collaborator OTHER

  • Seoul National University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-28
Primary Completion
2026-01-31
Completion
2026-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07278102 on ClinicalTrials.gov